Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus

Yuichiro Fujieda, Hiroshi Kataoka, Toshio Odani, Kotaro Otomo, Masaru Kato, Shinji Fukaya, Kenji Oku, Tetsuya Horita, Shinsuke Yasuda, Tatsuya Atsumi, Takao Koike

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

To characterize reversible posterior leukoencephalopathy syndrome (RPLS) in systemic lupus erythematosus (SLE) in terms of treatments for resolution and its clinical course, we reviewed 28 cases of RPLS in SLE including our cases in view of the treatment. Of these, 15 cases improved with blood pressure control and 13 required immunosuppressive therapy for activity of SLE presenting neurological manifestations. Patients without immunosuppressants at onset of RPLS more frequently required immunosuppressive therapy to recover it than those precedingly using these agents [31% (4/13) versus 87% (13/15), p = 0.008, chi-square test]. Brain magnetic resonance imaging (MRI) is important for diagnosis of RPLS-SLE in the patient with SLE who develops neurological disturbance and rapidly increasing blood pressure. When 7-day therapy for hypertension and convulsion does not reverse the manifestations, immunosuppressive treatments would be recommended to reverse RPLS.

Original languageEnglish
Pages (from-to)276-281
Number of pages6
JournalModern Rheumatology
Volume21
Issue number3
DOIs
Publication statusPublished - 2011 Jun 1
Externally publishedYes

Fingerprint

Posterior Leukoencephalopathy Syndrome
Systemic Lupus Erythematosus
Immunosuppressive Agents
Therapeutics
Blood Pressure
Chi-Square Distribution
Neurologic Manifestations
Seizures
Magnetic Resonance Imaging
Hypertension
Brain

Keywords

  • Magnetic resonance imaging (MRI)
  • Neuropsychiatric systemic lupus erythematosus (NPSLE)
  • Reversible posterior leukoencephalopathy syndrome (RPLS)
  • Systemic lupus erythematosus (SLE)

ASJC Scopus subject areas

  • Rheumatology

Cite this

Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. / Fujieda, Yuichiro; Kataoka, Hiroshi; Odani, Toshio; Otomo, Kotaro; Kato, Masaru; Fukaya, Shinji; Oku, Kenji; Horita, Tetsuya; Yasuda, Shinsuke; Atsumi, Tatsuya; Koike, Takao.

In: Modern Rheumatology, Vol. 21, No. 3, 01.06.2011, p. 276-281.

Research output: Contribution to journalReview article

Fujieda, Y, Kataoka, H, Odani, T, Otomo, K, Kato, M, Fukaya, S, Oku, K, Horita, T, Yasuda, S, Atsumi, T & Koike, T 2011, 'Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus', Modern Rheumatology, vol. 21, no. 3, pp. 276-281. https://doi.org/10.1007/s10165-010-0386-3
Fujieda, Yuichiro ; Kataoka, Hiroshi ; Odani, Toshio ; Otomo, Kotaro ; Kato, Masaru ; Fukaya, Shinji ; Oku, Kenji ; Horita, Tetsuya ; Yasuda, Shinsuke ; Atsumi, Tatsuya ; Koike, Takao. / Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. In: Modern Rheumatology. 2011 ; Vol. 21, No. 3. pp. 276-281.
@article{0794735632c54f13ae30690013f4e20b,
title = "Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus",
abstract = "To characterize reversible posterior leukoencephalopathy syndrome (RPLS) in systemic lupus erythematosus (SLE) in terms of treatments for resolution and its clinical course, we reviewed 28 cases of RPLS in SLE including our cases in view of the treatment. Of these, 15 cases improved with blood pressure control and 13 required immunosuppressive therapy for activity of SLE presenting neurological manifestations. Patients without immunosuppressants at onset of RPLS more frequently required immunosuppressive therapy to recover it than those precedingly using these agents [31{\%} (4/13) versus 87{\%} (13/15), p = 0.008, chi-square test]. Brain magnetic resonance imaging (MRI) is important for diagnosis of RPLS-SLE in the patient with SLE who develops neurological disturbance and rapidly increasing blood pressure. When 7-day therapy for hypertension and convulsion does not reverse the manifestations, immunosuppressive treatments would be recommended to reverse RPLS.",
keywords = "Magnetic resonance imaging (MRI), Neuropsychiatric systemic lupus erythematosus (NPSLE), Reversible posterior leukoencephalopathy syndrome (RPLS), Systemic lupus erythematosus (SLE)",
author = "Yuichiro Fujieda and Hiroshi Kataoka and Toshio Odani and Kotaro Otomo and Masaru Kato and Shinji Fukaya and Kenji Oku and Tetsuya Horita and Shinsuke Yasuda and Tatsuya Atsumi and Takao Koike",
year = "2011",
month = "6",
day = "1",
doi = "10.1007/s10165-010-0386-3",
language = "English",
volume = "21",
pages = "276--281",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus

AU - Fujieda, Yuichiro

AU - Kataoka, Hiroshi

AU - Odani, Toshio

AU - Otomo, Kotaro

AU - Kato, Masaru

AU - Fukaya, Shinji

AU - Oku, Kenji

AU - Horita, Tetsuya

AU - Yasuda, Shinsuke

AU - Atsumi, Tatsuya

AU - Koike, Takao

PY - 2011/6/1

Y1 - 2011/6/1

N2 - To characterize reversible posterior leukoencephalopathy syndrome (RPLS) in systemic lupus erythematosus (SLE) in terms of treatments for resolution and its clinical course, we reviewed 28 cases of RPLS in SLE including our cases in view of the treatment. Of these, 15 cases improved with blood pressure control and 13 required immunosuppressive therapy for activity of SLE presenting neurological manifestations. Patients without immunosuppressants at onset of RPLS more frequently required immunosuppressive therapy to recover it than those precedingly using these agents [31% (4/13) versus 87% (13/15), p = 0.008, chi-square test]. Brain magnetic resonance imaging (MRI) is important for diagnosis of RPLS-SLE in the patient with SLE who develops neurological disturbance and rapidly increasing blood pressure. When 7-day therapy for hypertension and convulsion does not reverse the manifestations, immunosuppressive treatments would be recommended to reverse RPLS.

AB - To characterize reversible posterior leukoencephalopathy syndrome (RPLS) in systemic lupus erythematosus (SLE) in terms of treatments for resolution and its clinical course, we reviewed 28 cases of RPLS in SLE including our cases in view of the treatment. Of these, 15 cases improved with blood pressure control and 13 required immunosuppressive therapy for activity of SLE presenting neurological manifestations. Patients without immunosuppressants at onset of RPLS more frequently required immunosuppressive therapy to recover it than those precedingly using these agents [31% (4/13) versus 87% (13/15), p = 0.008, chi-square test]. Brain magnetic resonance imaging (MRI) is important for diagnosis of RPLS-SLE in the patient with SLE who develops neurological disturbance and rapidly increasing blood pressure. When 7-day therapy for hypertension and convulsion does not reverse the manifestations, immunosuppressive treatments would be recommended to reverse RPLS.

KW - Magnetic resonance imaging (MRI)

KW - Neuropsychiatric systemic lupus erythematosus (NPSLE)

KW - Reversible posterior leukoencephalopathy syndrome (RPLS)

KW - Systemic lupus erythematosus (SLE)

UR - http://www.scopus.com/inward/record.url?scp=79960140762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960140762&partnerID=8YFLogxK

U2 - 10.1007/s10165-010-0386-3

DO - 10.1007/s10165-010-0386-3

M3 - Review article

C2 - 21225443

AN - SCOPUS:79960140762

VL - 21

SP - 276

EP - 281

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -